Clinical Trials for Non-Small Cell Lung Cancer

Phase II Study of Osimertinib (AZD9291) in Advanced NSCLC Patients With Exon 20 Insertion Mutations in EGFR

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

HealthScout AI summary: This trial involves adult patients with advanced NSCLC, specifically with EGFR exon 20 insertion mutations, who have received prior therapy, assessing the efficacy of osimertinib, a third-generation EGFR-tyrosine kinase inhibitor targeting these mutations.

ClinicalTrials.gov ID: NCT03191149

Pooled Mutant KRAS-Targeted Long Peptide Vaccine Combined With Nivolumab and Ipilimumab for Patients With Advanced KRAS Mutated Non-Small Cell Lung Cancer

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

HealthScout AI summary: This trial involves untreated patients with advanced KRAS-mutated non-small cell lung cancer (NSCLC) receiving a pooled mutant KRAS-targeted long peptide vaccine with poly-ICLC adjuvant, combined with nivolumab (PD-1 inhibitor) and ipilimumab (CTLA-4 inhibitor) to evaluate safety, feasibility, and efficacy. Eligible patients must have specific KRAS mutations and measurable disease.

ClinicalTrials.gov ID: NCT05254184

An Open-label Phase 1/2 Dose Finding, Safety and Efficacy Study of Oral NEO212 in Patients with Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Uncontrolled Brain Metastasis in Patients with Select Solid Tumors.

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

HealthScout AI summary: This clinical trial evaluates the safety and efficacy of the investigational drug NEO212, a novel conjugate of temozolomide and perillyl alcohol with enhanced brain penetration, in adults with Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype, or uncontrolled brain metastases from select solid tumors, including combinations with standard treatments like pembrolizumab or ipilimumab.

ClinicalTrials.gov ID: NCT06047379

A Phase 1/2 Study Evaluating the Safety and Efficacy of Amivantamab and Docetaxel Combination Therapy in Metastatic Non-small Cell Lung Cancer

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

HealthScout AI summary: This trial investigates the combination of amivantamab, an EGFR-MET bispecific antibody, and docetaxel in patients with metastatic NSCLC lacking oncogenic driver mutations, who have progressed on platinum-based chemotherapy and immune checkpoint inhibitors. The study focuses on determining the recommended Phase 2 dose and assessing the treatment's efficacy.

ClinicalTrials.gov ID: NCT06532032

A Phase 1/2 Study of Combination Lorlatinib and Ramucirumab in Patients With Advanced ALK-rearranged Lung Cancers

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

HealthScout AI summary: This trial enrolls adult patients with advanced ALK-rearranged NSCLC, including both treatment-naïve and those progressed on second-generation ALK TKIs, to assess the combination of lorlatinib, a third-generation ALK TKI, and ramucirumab, an anti-VEGFR2 monoclonal antibody.

ClinicalTrials.gov ID: NCT06007937

PROMISE-005: a Phase II Randomized Study Assessing the Efficacy of Stereotactic Body Radiotherapy (SBRT) in Patients with Oligometastatic Breast or Lung Cancer

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

HealthScout AI summary: The PROMISE-005 trial evaluates the efficacy of stereotactic body radiotherapy (SBRT) combined with standard care versus standard care alone in patients aged 18 or older with 1-5 oligometastases from metastatic breast cancer or non-small cell lung cancer, including those with targetable molecular alterations who have previously progressed on tyrosine kinase inhibitors. Participants receive SBRT to all detectable metastatic sites alongside ongoing systemic treatment, with an emphasis on improving progression-free survival.

ClinicalTrials.gov ID: NCT03808337

A Phase II Trial of Durvalumab (MEDI4736) and Tremelimumab in Combination With Chemotherapy in Virus-infected Patients With Non-small Cell Lung Cancer

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

HealthScout AI summary: This trial evaluates the combination of durvalumab, an anti-PD-L1 monoclonal antibody, and tremelimumab, an anti-CTLA-4 monoclonal antibody, with platinum-based chemotherapy in treating patients with stage IV NSCLC who are infected with HIV, HBV, or HCV.

ClinicalTrials.gov ID: NCT04499053

Local Consolidative Therapy (LCT) and Durvalumab (MEDI4736) for Oligoprogressive and Polyprogressive Stage III NSCLC After Chemoradiation and Anti-PD-L1 Therapy (ENDURE)

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

HealthScout AI summary: This trial targets patients with stage III NSCLC who experience oligoprogressive or polyprogressive disease post-chemoradiation and anti-PD-L1 therapy, evaluating the combination of local consolidative therapy (LCT) and durvalumab, an anti-PD-L1 immunotherapy, with the addition of systemic chemotherapy in polyprogressive cases.

ClinicalTrials.gov ID: NCT04892953

A Phase 1 / 2, Open Label, Study of Amivantamab (JNJ-61186372) Among Participants With Advanced NSCLC Harboring ALK, ROS1, and RET Gene Fusions in Combination With Tyrosine Kinase Inhibitors

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

HealthScout AI summary: This trial targets adult patients with advanced NSCLC harboring ALK, ROS1, and RET gene fusions who have progressed on at least one prior FDA-approved TKI, assessing the combination of the investigational bispecific antibody amivantamab, which targets EGFR and MET receptors, with current TKI therapies to overcome acquired resistance.

ClinicalTrials.gov ID: NCT05845671

An Open-label, Randomized, Multicenter, Phase 3 Study to Assess the Efficacy and Safety of Trastuzumab Deruxtecan as First-line Treatment of Unresectable, Locally Advanced, or Metastatic NSCLC Harboring HER2 Exon 19 or 20 Mutations (DESTINY-Lung04)

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

HealthScout AI summary: The trial evaluates Trastuzumab Deruxtecan, a HER2-targeted antibody-drug conjugate, as a first-line treatment for patients with unresectable, locally advanced, or metastatic non-squamous NSCLC with HER2 exon 19 or 20 mutations, comparing its efficacy and safety to the standard regimen of cisplatin or carboplatin, pembrolizumab, and pemetrexed. Participants must be treatment-naïve and have an ECOG performance status of 0-1.

ClinicalTrials.gov ID: NCT05048797